Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press135110.17650/1726-9776-2020-16-4-147-154DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. URINARY BLADDER CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак мочевого пузыряBladder cancer: what’s new in 2019—2020Рак мочевого пузыря: что нового в 2019-2020 гг.https://orcid.org/0000-0002-6112-2840KaryakinO. B.КарякинО. Б.
Russian Federation

4 Koroleva St., Obninsk 249031

Олег Борисович Карякин - заведующий отделением лучевого и хирургического лечения урологических заболеваний с группой брахитерапии рака предстательной железы, SPIN-код: 1486-9379/

249031 Обнинск, ул. Королева, 4

Karyakin@mrrc.obninsk.ruA.F. Tsyb Medical Radiological Research Center — branch of the National Medical Research Radiological Center, Ministry of Health of RussiaМедицинский радиологический научный центр им А.Ф. Цыба — филиал ФГБУ Национальный медицинский исследовательский центр радиологии Минздрава России301220201641471542310202014112020https://oncourology.abvpress.ru/oncur/article/view/1351

This review aims to summarize the latest data on the treatment of bladder cancer published during the specified period. Most of them are evidence-based and were obtained in randomized trials. A new classification based on molecular data was proposed at a consensus meeting of pathologists. A significant correlation has been demonstrated between life expectancy and morphological structure of the tumor. This article covers chemotherapy regimens for patient with BCG (Bacillus Calmette-Guerin) intolerance. Immunotherapeutic agents for muscle-invasive bladder cancer are being actively studied now; scientists are searching for the best treatment regimens with these drugs and their combinations with other antitumor agents. The European Association of Urology has developed a new classification of intraoperative adverse events and recommendations for pharmacotherapy and surgical treatment of patients with bladder cancer during the COVID-19 pandemic. In conclusion, the opinions of experts from the consensus meeting on the treatment of various forms of bladder cancer are given.

В обзоре представлены новые данные по лечению больных раком мочевого пузыря за указанный период. Большинство из них опубликовано на основании результатов рандомизированных исследований и имеет доказательный характер. На консенсусном митинге патоморфологов предложена новая классификация с учетом молекулярно-генетических данных. Показана четкая зависимость продолжительности жизни от морфологического строения опухоли. Представлены схемы химиотерапии в случае непереносимости вакцины БЦЖ (бациллы Кальмета—Герена). Иммунотерапевтические препараты для лечения мышечно-инвазивного рака мочевого пузыря все больше изучаются, и идет поиск последовательности их комбинаций с другими противоопухолевыми препаратами. Европейскими урологами предложена новая классификация побочных явлений, связанных с оперативными вмешательствами. Даны рекомендации по проведению лекарственного и хирургического лечения больных раком мочевого пузыря в период пандемии COVID-19. В заключении представлены мнения экспертов консенсусного митинга по лечению различных форм рака мочевого пузыря.

bladder cancermorphologyintravesical chemotherapyorgan-sparing treatmentimmunotherapycomplication of surgical treatmentCOVID-19consensus opinionрак мочевого пузыряморфологиявнутрипузырная химиотерапияорганосохраняющее лечениеиммунотерапияосложнение хирургического леченияCOVID-19консенсусное мнениеKamoun A., De Reynies A., Allory Y. et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol 2020;77(4):420-3. DOI: 10.1016/j.eururo.2019.09.006.Kamoun A, De Reyniès A, Allory Y, et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol. 2020 June; 77(4):420-423. DOI: 10.1016/j.eururo.2019.09.006.Yanagisawa T., Miki J., Sakanaka K. et al. MP73-03 clinical significance of horizontal and vertical margin of EN-BLOC TURBT specimen. J Urol 2020;203:1121-2. DOI: 10.1097/JU.0000000000000959.03.Yanagisawa T, Miki J, Sakanaka K, et al. MP73-03 clinical significance of horizontal and vertical margin of OF EN-BLOC TURBT specimen. J Urol. 2020 April; 203:1121-1122. DOI: 10.1097/JU.0000000000000959.03.Sathianathen N., Gantz J., Alarid-Escudero F. et al. MP73-07 intravesical chemotherapy for low grade bladder cancer: a cost analysis. J Urol 2020;203:1123-4. DOI: 10.1097/JU.0000000000000959.07.Sathianathen N, Gantz J, Alarid-Escudero F, et al. MP73-07 intravesical chemotherapy for low grade bladder cancer: a cost analysis. J Urol. 2020 April; 203:1123-1124. DOI: 10.1097/JU.0000000000000959.07Adele Caruso A., Ravishankar R., VanArsdalen K. et al. MP73-08 intravesical gemcitabine and docetaxol in heavily PRE-TREATED patients with non-muscle invasive bladder cancer (NMIBC). J Urol 2020;203:1123-4. DOI: 10.1097/JU.0000000000000959.08.Adele Caruso A, Ravishankar R, VanArsdalen K, et al. MP73-08 intravesical gemcitabine and docetaxol in heavily PRE-TREATED patients with non-muscle invasive bladder cancer (NMIBC). J Urol. 2020 April; 203:1123-1124. DOI: 10.1097/JU.0000000000000959.08Herr H. PD51-04 bladder - sparing surgery (BSS) for muscle invasive bladder cfncer (MIBC) after complete response to neoadjuvant chemotherapy (NAC). J Urol 2020;203:1084. DOI: 10.1097/JU.0000000000000953.04.Herr H. PD51-04 bladder – sparing surgery (BSS) for muscle invasive bladder cfncer (MIBC) after complete response to neoadjuvant chemotherapy (NAC). J Urol. 2020 April; 203:1084. DOI: 10.1097/JU.0000000000000953.04Kool R., Marcq G., Busca J. et al. PD60-01 definitive radiation-based therapy for muscle-invasive bladder cancer: the Canadian multicenter experience. J Urol 2020;203:1273. DOI: 10.1097/JU.0000000000000977.01.Kool R, Marcq G, Busca J, et al. PD60-01 definitive radiation-based therapy for muscle-invasive bladder cancer: the Canadian multicenter experience. J Urol. 2020 April; 203:1273. DOI: 10.1097/JU.0000000000000977.01.Shou J., Cao C., Jiang W. et al. PD51-07 oncologic and functional effectiveness of neoadjuvant chemotherapy followed by surgery plus concurrent chemoradiotherapy or cystectomy for muscle-invasive bladder cancer: preliminary results of a prospective phase II stude. J Urol 2020;203:1085. DOI: 10.1097/JU.0000000000000953.07.Shou J, Cao C, Jiang W, et al. PD51-07 oncologic and functional effectiveness of neoadjuvant chemotherapy followed by surgery plus concurrent chemoradiotherapy or cystectomy for muscle-invasive bladder cancer: preliminary results of a prospective phase II stude. J Urol. 2020 April; 203:1085. DOI: 10.1097/JU.0000000000000953.07).Nathan Suskovic N., Raldow A., Royce T. et al. PD55-03 cost-effectiveness of radical cystectomy vs. Trimodality therapy for muscle-invasive bladder cancer. J Urol 2020; 203:1182-3. DOI: 10.1097/JU.0000000000000965.03.Nathan Suskovic N, Raldow A, Royce T, et al. PD55-03 cost-effectiveness of radical cystectomy vs. Trimodality therapy for muscle-invasive bladder cancer. J Urol. 2020 April; 203:1182-1183. DOI: 10.1097/JU.0000000000000965.03).European Association of Urology. Guidelines 2020.European Association of Urology. Guidelines 2020 edition.Elsayed A., Zhe Jing Z., Osei J. et al. PD55-10 outcomes of robot-assisted radical cystectomy in North America vs Europe: results from the international robotic cystectomy consortium. J Urol 2020;203:1186. DOI: 10.1097/JU.0000000000000965.010.Elsayed A, Zhe Jing Z, Osei J, et al. PD55-10 outcomes of robot-assisted radical cystectomy in North America vs Europe: results from the international robotic cystectomy consortium. J Urol. 2020 April; 203:1186. DOI: 10.1097/JU.0000000000000965.010).Vuky J., Balar A.V., Castellano D. et al. Long-term outcomes in KEYNOTE-052: phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer. J Clin Oncol 2020;38(23):2658-66. DOI: 10.1200/JCO.19.01213.Vuky J, Balar AV, Castellano D, et al. Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer. Jour. Clin. Onc. 2020 August,38 (23):2658-2666. Doi.org/10.1200/JCO.19.01213).Grivas P., Plimack E.R., Balar A.V. et al. Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer (KEYNOTE-052): outcomes in older patients by age and performance status. Eur Urol Oncol 2020;3(3):351. DOI: 10.1016/j.euo.2020.02.009.Grivas P, Plimack ER, Balar AV, et al. Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status. Eur Urol Onc. 2020 June, 3 (3):351. DOI.org/10.1016/j.euo.2020.02.009).Necchi A., Raggi D., Bandini M. et al. PD51-01 interim results of PEANUT: an open-label, single-arm, phase 2 study evaluating pembrolizumab plus nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as salvage therapy for metastatic urothelial carcinoma (UC). J Urol 2020;203:1083. DOI: 10.1097/JU.0000000000000953.01.Necchi A, Raggi D, Bandini M, et al. PD51-01 interim results of PEANUT: an open-label, single-arm, phase 2 study evaluating pembrolizumab plus nanoparticle albumin-bound paclitaxel (nab- paclitaxel) fs salvage therapy for metastatic urothelial carcinoma (UC). J Urol. 2020 April; 203:1083. DOI: 10.1097/JU.0000000000000953.01.Biyani C.S., Pecanka J., Roupret M. et al. Intraoperative Adverse Incident Classification (EAUiaiC) by the European Association of Urology ad hoc Complications Guidelines Panel. Eur Urol 2020;77(5):601-10. DOI: 10.1016/j.eururo.2019.11.015.Biyani CS, Pecanka J, Rouprêt M, et al. Intraoperative Adverse Incident Classification (EAUiaiC) by the European Association of Urology ad hoc Complications Guidelines Panel. Eur Urol. 2020 May.77 (5):601-610. DOI.org/10.1016/j.eururo.2019.11.015.Gillessen S., Powles T. Advice regarding systemic therapy in patients with urological cancers during the COVID-19 pandemic. Eur Urol 2020;77(6):667-8. DOI: 10.1016/j.eururo.2020.03.026.Gillessen S, Powles T. Advice Regarding Systemic Therapy in Patients with Urological Cancers During the COVID-19 Pandemic. Eur Urol. 2020 June. 77 (6):667-668. DOI.org/10.1016/j.eururo.2020.03.026Stensland K.D., Morgan T.M., Moinzadeh A. et al. Considerations in the triage of urologic surgeries during the COVID-19 pandemic. Eur Urol 2020;77(6):663-6. DOI: 10.1016/j.eururo.2020.03.027.Stensland KD, Morgan TM, Moinzadeh A, et al. Considerations in the Triage of Urologic Surgeries During the COVID-19 Pandemic. Eur Urol, 2020 Apr, 77(6):663-666. DOI.org/10.1016/j.eururo.2020.03.027Witjes J.A., Babjuk M., Bellmunt J. et al. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer - an international collaborative multistakeholder effort: under the auspices of the EAU-ESMO Guidelines Committees. Eur Urol 2020;77(2):223-50. DOI: 10.1016/j.eururo.2019.09.035.Witjes JA, Babjuk M, Bellmunt J, et al. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort† : Under the Auspices of the EAU-ESMO Guidelines Committees. Eur Urol. 2020 February. 77(2): 223-250. DOI.org/10.1016/j.eururo.2019.09.035.